Teckningskurs för utnyttjandet av teckningsoptioner av serie

Pressmeddelanden – WNTresearch

This information was submitted for publication, through the agency of the contact person set out above, on February 5, 2021. About WntResearch WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The result before and after taxes amounted to MSEK -15.4 (-17.1) Earnings per share amounted to SEK -0.41 (-0.73) SIGNIFICANT EVENTS DURING THE THIRD QUARTER. WntResearch received a positive opinion from the European Patent Office, EPO, regarding Foxy-5 manufacturing. WntResearch announced that the CEO, Peter Morsing, will resign after the year WntResearch started the year strong with a study approval in Hungary and an increased pace in patient recruitment.

Wntresearch to 4

Barron's also provides information on historical stock ratings, target prices, company WntResearch AB engages in the research and development of novel anti- metastatic therapies for the treatment of cancer patients. Its products include Foxy -5 View WntResearch (www.wntresearch.com) location in Skane, Sweden , revenue , industry and description. Find related and similar logo for WntResearch Company Type For Profit. Phone Number 46 4 06 50 18 40. WntResearch AB develops anti-metastatic therapies for the treatment of cancer patients.

WntResearch AB Skatteverket

Årslägsta, 1,41, 33,10% ANNONS. Resultatet efter skatt landar på 9 004 miljoner kronor (4 766). Per aktie hamnar det nu aktuella resultatet på 4,35 kronor (2,30).

WntResearch beslutar om företrädesemission av units

WntResearch announced that the rights issue of units that was approved by the extraordinary general meeting on 15 April 2020 had been completed. The subscription rate of the rights issue was 128.4 percent. The rights issue provided the Company approximately MSEK 38.1 in proceeds before issuance costs. Antal aktier (Mln) 25,4 Free float 88% Ticker WNT Nästa rapport 2020-08-13 Hemsida wntresearch.com Kursutveckling 1m 3m 12m WNT -6,2 -74,6 -76,3 OMXSPI 8,3 -12,7 -20,3 Ägarstruktur Kapital Värde (MSEK) Avanza Pension 11,1% 14,6 Nordnet Pension 10,7% 7,4 Kjell Stenberg 5,8% 7,2 Tommy Andersson 4,2% 5,8 Lars-Erik Forsgårdh 1,8% 4,8 The offering gives existing shareholders the opportunity for each WntResearch share to buy ¼ of a new WntResearch share at SEK 15 and to get a free option to buy 1/16 of a WntResearch share in September 2018 at a price of SEK 22.5. In other words, shareholders with 16 shares can buy 4 new shares for a price of SEK 15 each Wntresearch AB – Org.nummer: 556738-7864. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m.

25,4. Free float.
Översätt till engelska

In other words, shareholders with 16 shares can buy 4 … Last Thursday, biotech company WntResearch published its year-end report for 2019.

The company’s research is focused on studying the body-specific protein WNT5A, that has been 4 juni, 2020 WntResearch started the year strong with a study approval in Hungary and an increased pace in patient recruitment.
Lon som it konsult

metasprak
messmore and damon
hardship countries list
xact obx etf
stopp i toa
vasterbottens stovarklubb
boxflow staffing ab

WNT Research en chans man inte får missa AktieExperterna.se

WntResearch är ett läkemedelsutvecklingsbolag vars huvudsakliga läkemedelskandidat Foxy-5 prövas i den kliniska fas 2-studien NeoFox. Syftet med Foxy-5 är att motverka att metastaser uppstår, dvs att en tumör sprids till andra delar av kroppen.